StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) ("StageZero" or the "Company") today announced that it will host a conference call as part of its Special and Annual General Meeting of Shareholders on Wednesday June 7, 2023, so that all shareholders may follow along with the proceedings of the meeting.

Annual General and Special Meeting Conference Call

Event Date: Wednesday June 7, 2023
Time: 2:00pm ET
Webcast Link: https://www.gowebcasting.com/12586

Conference Call Numbers

Canada/USA TF: 1-800-319-4610
Toronto Toll: +1-416-915-3239
International Toll: +1-604-638-5340

About StageZero Life Sciences, Ltd.

StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT™).

The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

Aristotle® is processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company provides patients with multiple clinical programs, for risk management and treatment, through its subsidiary Care Oncology.

StageZero Life Sciences, Ltd. trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.

For further information please contact:

Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/168820

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).
LinkedIn
StockTwits
Twitter